Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cryopreserved Platelet
Therapeutic Area : Hematology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cellphire Stops Phase 2/3 CRYPTICS Study Early for Efficacy
Details : CLPH-511, Cellphire’s investigational cryopreserved platelet product (CPP), is being developed for the treatment of uncontrolled hemorrhage in patients undergoing cardiopulmonary bypass surgery.
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
April 22, 2025
Lead Product(s) : Cryopreserved Platelet
Therapeutic Area : Hematology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cryopreserved Platelet
Therapeutic Area : Hematology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cellphire Therapeutics CLPH-511 Fast Track Designation Granted
Details : CLPH-511 (frozen activated platelets) injectable suspension is being evaluated for the treatment of acute hemorrhage as an alternative to conventional platelets when not available or in short supply.
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
March 17, 2025
Lead Product(s) : Cryopreserved Platelet
Therapeutic Area : Hematology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Thrombosomes
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Recipient : Jakob Stensballe
Deal Size : Inapplicable
Deal Type : Inapplicable
Thrombosomes® in Acute Thoracic Aortic Dissections
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 16, 2023
Lead Product(s) : Thrombosomes
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Recipient : Jakob Stensballe
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Hematology
Study Phase : Phase II
Sponsor : Simcah Management
Deal Size : $15.0 million
Deal Type : Series A Financing
Cellphire Therapeutics, Inc. Closes $15 Million Series A Funding Round Led by Simcah Management
Details : This financing round enables Cellphire to expand and accelerate the development of Thrombosomes® and support the company's groundbreaking research and development projects in the areas of targeted drug delivery, anti-thrombotic reversal, and regenerativ...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 04, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Hematology
Highest Development Status : Phase II
Sponsor : Simcah Management
Deal Size : $15.0 million
Deal Type : Series A Financing
Lead Product(s) : Human Platelets
Therapeutic Area : Undisclosed
Study Phase : Phase II/ Phase III
Sponsor : U.S. Army Medical Research and Development Command
Deal Size : Inapplicable
Deal Type : Inapplicable
DMSO Cryopreserved Platelets in Cardiopulmonary Bypass Surgery (CRYPTICS)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 14, 2021
Lead Product(s) : Human Platelets
Therapeutic Area : Undisclosed
Highest Development Status : Phase II/ Phase III
Sponsor : U.S. Army Medical Research and Development Command
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Thrombosomes
Therapeutic Area : Hematology
Study Phase : Phase II
Sponsor : Department of Health and Human Services
Deal Size : Inapplicable
Deal Type : Inapplicable
Thrombosomes® in Bleeding Thrombocytopenic Patients Study
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 17, 2020
Lead Product(s) : Thrombosomes
Therapeutic Area : Hematology
Highest Development Status : Phase II
Sponsor : Department of Health and Human Services
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Thrombosomes
Therapeutic Area : Hematology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Thrombosomes for Expanded Access Use
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 06, 2020
Lead Product(s) : Thrombosomes
Therapeutic Area : Hematology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Thrombosomes
Therapeutic Area : Hematology
Study Phase : Phase I
Sponsor : Department of Health and Human Services
Deal Size : Inapplicable
Deal Type : Inapplicable
Thrombosomes® in Bleeding Thrombocytopenic Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 09, 2018
Lead Product(s) : Thrombosomes
Therapeutic Area : Hematology
Highest Development Status : Phase I
Sponsor : Department of Health and Human Services
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Thrombosomes
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Department of Health and Human Services
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 22, 2014
Lead Product(s) : Thrombosomes
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Department of Health and Human Services
Deal Size : Inapplicable
Deal Type : Inapplicable